Case study of patents related to captopril, Squibb’s first blockbuster

References

• Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761–776.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death; 2012. [cited 2016 Jul 25]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
   Google Scholar
• Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42–50.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis. 2012;2(3):160–170.
   PubMedGoogle Scholar
• Mendoza A, Lazartigues E. The compensatory renin–angiotensin system in the central regulation of arterial pressure: new avenues and new challenges. Ther Adv Cardiovasc Dis. 2015;9(4):201–208.
   PubMedGoogle Scholar
• Top 20 Global Therapy Areas 2014. IMS Health Intelligence Applied. London, UK: IMS Health HQ Limited; 2014. [cited 2016 Apr 18]. Available from: https://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/2014/Top_20_Global_Therapy_Classes_2014.pdf.
   Google Scholar
• Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology. 1994;50:399–409.
   PubMedGoogle Scholar
• Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a “Class of Agents”? Circulation. 2003;108(21):2608–2610.
   PubMed Web of Science ®Google Scholar
• Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nat Med. 1999;5(10):1110–1113.
   PubMed Web of Science ®Google Scholar
• Erdös EG. The ACE and I: how ACE inhibitors came to be. FASEB J. 2006;20(8):1034–1038.
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Bartelt DC, Greenet LJ. Isolation of bradykinin-potentiating peptides from bothrops jararaca venom. Biochemistry. 1970;9(13):2583–2593.
   PubMed Web of Science ®Google Scholar
• Krieger EM, Salgado HC, Assan CJ, et al. Potential screening test for detection of overactivity of renin-angiotensin system. Lancet. 1971;1:269–271.
   PubMed Web of Science ®Google Scholar
• Byers LD, Wolfenden R. A potent reversible inhibitor of carboxypeptidase A. J Biol Chem. 1972;247:606–608.
   PubMed Web of Science ®Google Scholar
• Cushman DW, Cheung HS, Sabo EF, et al. Design of potent competitive inhibitors of angiotensin-converting enzyme carboxyalkanoyl and mercaptoalkanoyl aminoacids. Biochemistry. 1977;16:5484–5491.
   PubMed Web of Science ®Google Scholar
• World Intellectual Property Organization. Patents. intellectual property primer course. Switzerland: WIPO; 2014. Online Course.
   Google Scholar
• Neugebauer J, ER SQUIBB & SONS INC. Azetidine-2-carboxylic acid derivatives. US4046889. 1977.
   Google Scholar
• ER SQUIBB & SONS INC. Pyroglutamic acid derivatives and analogs. US4234489. 1980.
   Google Scholar
• ER SQUIBB & SONS INC. Mercaptoacyldihydropyrazole carboxylic acid derivatives. US4266065. 1981.
   Google Scholar
• ER SQUIBB & SONS INC. Mercaptoacyl derivatives of 4-oxazolidine-carboxylic acids. US4321392. 1982.
   Google Scholar
• ER SQUIBB & SONS INC. S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics. US4482725. 1984.
   Google Scholar
• ER SQUIBB & SONS INC. Substituted 4-phenoxy or 4-phenylthio pralines. US4536501. 1985.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Diazepine containing dual action inhibitors. US5646276. 1997.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Compounds containing a fused bicycle ring and processes therefor. US5508272. 1996.
   Google Scholar
• Romagnolo D, Polan CE, Barbeau WE, BRISTOL MYERS SQUIBB. Substituted azepino[2,1-a]isoquinoline compounds. US5362727. 1994.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Azepinone compounds useful in the inhibition of ACE and NEP. US5587375. 1996.
   Google Scholar
• Chadwick BP, Campbell LJ, Jackson CL, et al. BRISTOL MYERS SQUIBB. Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP. US5877313. 1999.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Diazepine containing dual action inhibitors. US5635504. 1997.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Thiazolo benzazepine containing dual action inhibitors. EP747393. 1996.
   Google Scholar
• ER SQUIBB & SONS INC. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase. US5552397. 1996.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Benzo-fused lactams. US5504080. 1996.
   Google Scholar
• Kellici TF, Liapakis G, Tzakos AG, et al. Pharmaceutical compositions for antihypertensive treatments: a patent review. Expert Opin Ther Pat. 2015;25(11):1305–1317.
   PubMed Web of Science ®Google Scholar
• BRISTOL MYERS SQUIBB CO. Angiotensin converting enzyme (ace) inhibitors containing a fused multiple ring lactam. EP657453. 1995.
   Google Scholar
• ER SQUIBB & SONS INC. Phosphinylalkanoyl substituted 4,5-dihydropyrazole-5-carboxylic acid derivatives and hypotensive method and composition. US4371526. 1983.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein. WO2003043624. 2003.
   Google Scholar
• ER SQUIBB & SONS INC. Reaction products of pyrazolo[1,5-c]quinazoline derivatives and proline derivatives and methods for reducing blood pressure while inhibiting allergic reactions with them. US4307099. 1981.
   Google Scholar
• ER SQUIBB & SONS INC. Phosphonate substituted amino acids useful as antihypertensives. US5102875. 1992.
   Google Scholar
• ER SQUIBB & SONS INC. Derivatives of mercaptoacyl amino acids. GB2050359. 1981.
   Google Scholar
• ER SQUIBB & SONS INC. Acylalkylaminocarbonyl substituted amino and imino acid compounds. EP103496. 1984.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring. US5616775. 1997.
   Google Scholar
• Miyoshi T, Hanazawa S, Hirose K, et al. ER SQUIBB & SONS INC. Process and intermediates for preparing trans-4-substituted-s-prolines. US4588819. 1986.
   Google Scholar
• ER SQUIBB & SONS INC. Purification of mercaptoacyl amino acids. US4332726. 1982.
   Google Scholar
• ER SQUIBB & SONS INC. Inhibitors of mammalian collagenase. US4235885. 1980.
   Google Scholar
• ER SQUIBB & SONS INC. Heterocyclic containing amides as inhibitors of mammalian collagenase. US4263293. 1980.
   Google Scholar
• Verdi RJ, Barbano DM, ER SQUIBB & SONS INC. Enkephalinase inhibitors. US4722810. 1988.
   Google Scholar
• BRISTOL MYERS SQUIBB CO. Sustained release formulation containing captopril and method. US5433951. 1995.
   Google Scholar
• ER SQUIBB & SONS INC. Captopril formulation providing increased duration of activity. US5158777. 1992.
   Google Scholar
• Verdi RJ, Barbano DM, ER SQUIBB & SONS INC. Controlled release formulation and method. US4738850. 1988.
   Google Scholar
• ER SQUIBB & SONS INC. Hydroxy substituted peptide compounds. US4514391. 1985.
   Google Scholar
• ER SQUIBB & SONS INC. Phosphonamidate compounds. US4432972. 1984.
   Google Scholar
• BRISTOL-MYERS SQUIBB CMPANY. HMG-CoA reductase inhibitors and method. US7371759. 2005.
   Google Scholar
• BRISTOL-MYERS SQUIBB COMPANY. HMG-CoA reductase inhibitors and method. US7420059. 2005.
   Google Scholar
• RESET THERAPEUTICS INC. Carbazole-containing sulfonamides as cryptochrome modulators. WO2013170186. 2013.
   Google Scholar
• WOCKHARDT LIMITED. Methods for treating cardiovascular disorders. WO2013030725. 2013.
   Google Scholar
• Gradman AH. Strategies for combination therapy in hypertension. Curr Opin Nephrol Hypertens. 2012;21(5):486–491.
   PubMed Web of Science ®Google Scholar
• Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26(12):2877–2887.
   PubMed Web of Science ®Google Scholar
• Von lueder TG, Atarb D, Kruma H, et al. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014;144(1):41–49.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51(5):519–528.
   PubMed Web of Science ®Google Scholar